



The Reliable Resource for the Biomedical Community

June 2011

Featured Histology Capabilities at CBI

Assessment of neural degeneration and apoptosis in neonatal brains of primates and smaller laboratory animals treated with ketamine

Apoptosis and neural degeneration stains

- Activated Caspase
- TUNEL
- Fluoro Jade
- Silver Stains
- GFAP

⋮

For more information, contact Mike Zamora mike_zamora@compbio.com

Quick Links

- [Contact Us](#)
- [Our Website](#)
- [About CBI](#)

Join Our Mailing List!

Comparative Biosciences, Inc.
786 Lucerne Drive
Sunnyvale, CA 94085

Over the past 6 years, the USDA has spent over \$115M in Animal Welfare enforcement

Annual appropriations for enforcement of the Animal Welfare Act by the USDA (from USDA website):

2010	\$23,330,000
2009	\$21,522,000
2008	\$20,643,000
2007	\$17,473,000
2006	\$17,303,000
2005	\$16,485,000

Note that spending on enforcement by USDA increased by over 40%, roughly four times the rate of inflation, over the period. For comparison, the NIH budget increased by 7% over the same period.

New Drugs Approved in May 2011

- **Afinitor (everolimus)**; Novartis; Advanced pancreatic neuroendocrine tumors
- **Sutent (sunitinib malate)**; Pfizer; Pancreatic neuroendocrine tumors
- **Tradjenta (linagliptin)**; Boehringer Ingelheim; Treatment of type II diabetes

Rabbit laser-induced choroidal neovascularization

CBI is proud to announce that we have developed and validated a **Laser-Induced Choroidal Neovascularization Model in Rabbits**. The

Phone: 408.738.9260
Fax: 408.738.9278

development of this model is the result of nearly 2 years of investigation and experimentation. In this model, we place 10-15 lesions in the retina using a unique lasering process developed by CBI. The lesions form consistently and are composed of a fibrovascular plaque containing new small capillaries typical of neovascularization. Rabbits are examined funduscopically and histopathologically. Lesions are assessed histomorphometrically for area and volume of lesion size. Treatment is reflective of the individual study protocol.

For information on pre-clinical ophthalmic pharmacokinetics, efficacy modeling and toxicology services offered at CBI, contact Mike Zamora, Business Development Manager

Tel: 408-738-9265

Email: mike_zamora@compbio.com

[Forward email](#)



This email was sent to nidya_zamarron@compbio.com by nidya_zamarron@compbio.com | [Update Profile/Email Address](#) | Instant removal with [SafeUnsubscribe™](#) | [Privacy Policy](#).

Comparative Biosciences, Inc. | 786 Lucerne Drive | Sunnyvale | CA | 94085